Administration of insulin like growth factor I (IGF I) lowers serum lipoprotein(a)-impact on atherosclerotic cardiovascular disease
出版年份 2023 全文链接
标题
Administration of insulin like growth factor I (IGF I) lowers serum lipoprotein(a)-impact on atherosclerotic cardiovascular disease
作者
关键词
-
出版物
GROWTH HORMONE & IGF RESEARCH
Volume 71, Issue -, Pages 101548
出版商
Elsevier BV
发表日期
2023-07-22
DOI
10.1016/j.ghir.2023.101548
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Lipoprotein Apheresis: Current Recommendations for Treating Familial Hypercholesterolemia and Elevated Lipoprotein(a)
- (2023) Maya S. Safarova et al. Current Atherosclerosis Reports
- The Potential Clinical Benefit of Lowering Lipoprotein(a)
- (2022) Brian A. Ference JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement
- (2022) Florian Kronenberg et al. EUROPEAN HEART JOURNAL
- Increase of serum lipoprotein (a), an adverse effect of growth hormone treatment
- (2022) Zvi Laron GROWTH HORMONE & IGF RESEARCH
- Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease
- (2022) Michelle L. O’Donoghue et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of PCSK9 inhibitor on lipoprotein particles in patients with acute coronary syndromes
- (2021) Tingting Li et al. BMC Cardiovascular Disorders
- The history, physiology and treatment safety of growth hormone
- (2021) Anders Tidblad ACTA PAEDIATRICA
- Lipoprotein(a) Reduction in Persons with Cardiovascular Disease
- (2020) Sotirios Tsimikas et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lipoprotein(a) and Cardiovascular Diseases ― Revisited ―
- (2020) Albert Youngwoo Jang et al. CIRCULATION JOURNAL
- Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial
- (2020) Michael Szarek et al. EUROPEAN HEART JOURNAL
- Association of Childhood Growth Hormone Treatment With Long-term Cardiovascular Morbidity
- (2020) Anders Tidblad et al. JAMA Pediatrics
- 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk
- (2019) François Mach et al. ATHEROSCLEROSIS
- Lipoprotein(a)-Lowering by 50 mg/dL (105 nmol/L) May Be Needed to Reduce Cardiovascular Disease 20% in Secondary Prevention
- (2019) Christian M. Madsen et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- HEART UK consensus statement on Lipoprotein(a): A call to action
- (2019) Jaimini Cegla et al. ATHEROSCLEROSIS
- Structure, function, and genetics of lipoprotein (a)
- (2016) Konrad Schmidt et al. JOURNAL OF LIPID RESEARCH
- Effects of Extended-Release Niacin with Laropiprant in High-Risk Patients
- (2014) NEW ENGLAND JOURNAL OF MEDICINE
- Cardiometabolic Aspects of the Polycystic Ovary Syndrome
- (2012) Harpal S. Randeva et al. ENDOCRINE REVIEWS
- Genetically Elevated Lipoprotein(a) and Increased Risk of Myocardial Infarction
- (2009) Pia R. Kamstrup JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- A novel function of lipoprotein [a] as a preferential carrier of oxidized phospholipids in human plasma
- (2008) Claes Bergmark et al. JOURNAL OF LIPID RESEARCH
- A More Atherogenic Serum Lipoprotein Profile Is Present in Women with Polycystic Ovary Syndrome: A Case-Control Study
- (2007) Olivier Valkenburg et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started